CGON Shorts Ease, But Options Traders Grow More Cautious Ahead of November Print

The Street remains broadly constructive, though the last formal analyst actions, all dated early August, show a mixed undertone. Following the Q2 print, Piper Sandler and Truist both nudged targets higher and maintained positive ratings, while RBC Capital trimmed its target by $2 to $79, keeping its Outperform. The consensus mean target of around $91 sits well above the current price of $59.85, implying more than 50% upside on paper. That gap partly reflects the stock's 17% slide over the past month. Bulls point to the 76% complete response rate in BOND-003 Cohort C and the $1 billion cash runway through 2029. Bears counter that this is a single-asset clinical-stage company, that TAR-200 could take outsized share on reimbursement dynamics, and that approval delays would be materially damaging. The factor scores add some texture: the EPS surprise percentile ranks at 82 and the 90-day EPS momentum score at 80 suggest the company has been exceeding estimates, but the short score percentile of 14 indicates ORTEX ranks this as a relatively low-risk-from-shorts stock despite the 13% float figure, consistent with the soft borrow market.

Ownership adds a layer of complexity. ORTEX's EDGAR data confirms two active Schedule 13D filers on the register: Patrick G. Enright at a last-disclosed 6.0% stake and Brian Liu, who filed a 13D/A amendment in October 2025 and executed a $24.8 million open-market purchase in June 2026 at $66.87 per share under a 10b5-1 plan. That purchase, the largest insider transaction in the recent filing history, was made at a price well above where the stock trades today. The activist 13D filings are worth noting because they signal an intent to engage beyond passive holding, though the stakes were last disclosed more than a year ago and positions around the 5% threshold can change without a further filing. On the institutional side, T. Rowe Price added 372,000 shares in the quarter to September and BlackRock added 1.2 million, while Wellington Management trimmed from 7.2% to 6.0% of class per its August 13D/G amendment.

Earnings history for the stock is short but benign. The four available prints produced one-day moves of plus 3.7%, plus 2.3%, minus 1.3%, and plus 0.2%, a pattern of muted post-event reactions that stands in contrast to the binary trial risk baked into the narrative. The five-day reactions have been similarly contained except for the June 4 print, which saw a 5.9% gain over the following week.

With the BLA submission for HR-NMIBC on track for completion in Q4 2026 and PIVOT-006 topline data expected in the near term, the November 12 print is likely to be read less as a quarterly numbers exercise and more as an opportunity for management to update timelines on those two catalysts, making the binary data calendar the variable that matters most for how the stock trades into year-end.